| Date/App# |
 List of recent Antibodies-related patents |
01/22/15
20150024960 |   Multiple biomarker set for breast cancer diagnosis, detecting the same, and diagnosis kit for breast cancer using antibody against the same
The present invention relates to a biomarker set for diagnosing breast cancer comprising two or more protein markers of: apolipoprotein c1, apolipoprotein (a), neural cell adhesion molecule l1-like protein, carbonic anhydrase 1, and fibronectin; a method for detecting the biomarker set in a blood sample through a multiple reaction monitoring; a kit for diagnosing breast cancer comprising antibodies specific to each of the proteins of the biomarker set; and a method for detecting proteins of the marker set in a blood sample through an antigen-antibody binding reaction. The method for detecting the protein marker set in a blood sample by the mrm method or antigen-antibody binding reaction and the diagnostic kit can provide very high accuracy and sensitivity in comparison with the diagnosis method using a single marker and can very conveniently diagnose breast cancer using blood from patients, thereby being effectively used for early diagnosis of breast cancer..
Biomedieng Co., Ltd. |
01/22/15
20150024944 |  Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hosts
The present disclosure provides methods of integrating therapeutic protein and antibody generation and/or selection, evolution and expression in a eukaryotic host for manufacturing in a single system. Therapeutic proteins, including antibodies, are generated, optimized and manufactured in the same eukaryotic host system.
Bioatla, Llc |
01/22/15
20150024512 |  Method for selectively quantifying a-beta aggregates
The invention relates to methods for selectively quantifying a-beta aggregates, comprising the immobilization of anti-a-beta antibodies on a substrate, application of the sample to be tested onto the substrate, addition of probes labeled for detection, which mark these by specific binding to a-beta aggregates and detection of the marked aggregates.. .
Forschungszentrum Juelich Gmbh |
01/22/15
20150024500 |  Methods and compositions for producing double allele knock outs
The present invention provides a method and compositions utilizing the crispr system to disrupt a target gene in eukaryotic cells to produce double allele knock outs. The method finds use in producing afucosylated antibodies with enhanced adcc activity..
Larix Bioscience, Llc |
01/22/15
20150024484 |  Antibody inhibitors of gdf-8 and uses thereof
The disclosure provides novel antibodies against growth and differentiation factor-8 (gdf-8), including antibody fragments, which inhibit gdf-8 activity in vitro and in vivo. The disclosure also provides methods for diagnosing, preventing, or treating degenerative disorders of muscle, bone, or insulin metabolism..
Wyeth Llc |
01/22/15
20150024457 |  Antibodies to troponin i and methods of use thereof
The subject invention relates to antibodies to troponin i as well as methods of use thereof. In particular, such antibodies may be used to detect troponin i in a patient and may also be used in the diagnosis of, for example, a myocardial infarction or acute coronary syndrome..
Abbott Laboratories |
01/22/15
20150024433 |  Humanized antibodies that recognize alpha-synuclein
The present application discloses humanized 1h7 antibodies. The antibodies bind to human alpha synuclein and can be used for treatment and diagnosis of lewy body disease..
Neotope Biosciences Limited |
|
|
01/22/15
20150024432 |  Methods for identifying immunobinders of cell-surface antigens
The invention provides methods for identifying immunobinders, such as scfv antibodies, capable of specifically binding to cell surface antigens, and compositions identified according to said methods.. .
Esbatech, An Alcon Biomedical Research Unit Llc |
01/22/15
20150024417 |  Peptides, devices, and methods for the detection of ehrlichia antibodies
The invention provides compositions (e.g., peptide compositions) useful for the detection of antibodies that bind to ehrlichia antigens. The peptide compositions comprise polypeptide sequences based on an immunogenic fragment of the ehrlichia outer membrane protein 1 (omp-1) protein.
Abaxis, Inc. |
01/22/15
20150024404 |  Assays for the detection of anti-tnf drugs and autoantibodies
The present invention provides assays for detecting and measuring the presence or level of anti-tnfα drug therapeutics and autoantibodies in a sample. The present invention is useful for optimizing therapy and monitoring patients receiving anti-tnfα drug therapeutics to detect the presence or level of autoantibodies (e.g., haca and/or haha) against the drug..
Nestec S.a. |
01/22/15
20150024005 | Augmentation of titer for vaccination in animals
The disclosure relates to a composition added to animal feed used in combination with a vaccine to enhance the effectiveness of the vaccine. Amongst other effects, the composition raises the titer of antibodies to the vaccine..
Omnigen Research, L.l.c. |
01/22/15
20150023999 | Novel targets of acinetobacter baumannii
The present invention provides antigenic polypeptides expressed during an infection by a pathogenic organism, such as acinetobacter and compositions comprising these polypeptides. The invention further provides compositions for use in treating, preventing or detecting a bacterial infection, in particular vaccine compositions using the antigenic polypeptides.
Aridis Pharmaceuticals |
01/22/15
20150023982 | Methods of administering anti-tnfalpha antibodies
Methods of treating disorders in which tnfα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (htnfα) are disclosed. The antibody may be administered with or without methotrexate.
Abbvie Biotechnology Ltd. |
01/22/15
20150023979 | Antibodies against e7 protein of human papilloma virus (hpv)
The invention discloses a method for preparing human papilloma virus protein e7 antigen (hpv e7 antigen) comprising the following steps: —providing a purified preparation of hpv protein e7; —phosphorylating the hpv protein e7 in the preparation; —purifying the phosphorylated e7 protein with an anion exchange chromatography, wherein the phosphorylated e7 protein is separated from the non-phosphorylated e7 protein by a step wherein the non-phosphorylated e7 protein stays bound to an anion exchanger during the anion exchange chromatography whereas the phosphorylated e7 protein is obtained in the eluate of the anion exchange chromatography, thereby—obtaining a purified preparation of a phosphorylated hpv protein e7 antigen. The invention further discloses antibodies specific to this antigen, a kit and method for using such antibodies in clinical diagnostics and methods for generation of such antibodies..
Valdospan Gmbh |
01/22/15
20150023978 | Anti mif antibodies
The present invention relates to monoclonal antibodies and antigen-binding portions thereof that specifically bind to the c-terminal or the center region of macrophage migration inhibitory factor (mif). These anti-mif antibodies and antigen-binding portions thereof further inhibit human mif biological function.
Baxter Healthcare Sa |
01/22/15
20150023976 | Antibody polypeptides that antagonize cd40l
Antibody polypeptides that specifically bind human cd40l are provided. The antibody polypeptides do not activate platelets.
Domantis Limited |
01/22/15
20150023964 | Fcgammariib-specific antibodies and methods of use thereof
The present invention relates to antibodies or fragments thereof that specifically bind fcγriib, particularly human fcγriib, with greater affinity than the antibodies or fragments thereof bind fcγriia, particularly human fcγriia. The present invention also provides the use of an anti-fcγriib antibody or an antigen-binding fragment thereof, as a single agent therapy for the treatment, prevention, management, or amelioration of a cancer, preferably a b-cell malignancy, particularly, b-cell chronic lymphocytic leukemia or non-hodgkin's lymphoma, an autoimmune disorder, an inflammatory disorder, an ige-mediated allergic disorder, or one or more symptoms thereof.
Macrogenics, Inc. |
01/22/15
20150023957 | Saa domain-specific antibodies and peptide antagonists and use thereof to treat inflammatory diseases
Isolated saa peptides, fusion proteins and compositions comprising such are provided as are domain-specific saa antibodies. Methods of treating sepsis and endotoxemia are also provided..
The Feinstein Institute For Medical Research |
01/22/15
20150023956 | Methods and compositions for increasing enzyme activity in the cns
Provided herein are methods and compositions for treating a subject suffering from an enzyme deficiency in the central nervous system (cns). The bifunctional fusion antibodies provided herein comprise an antibody to an endogenous blood brain barrier (bbb) receptor and an enzyme deficient in mucopolysaccharidosis iii (mps-iii).
Armagen Technologies, Inc. |
01/22/15
20150023954 | Potentiating antibody-induced complement-mediated cytotoxicity via pi3k inhibition
Methodologies and technologies for potentiating antibody-based cancer treatments by increasing complement-mediated cell cytotoxicity are disclosed. Further provided are methodologies and technologies for overcoming ineffective treatments correlated with and/or caused by sub-lytic levels of complement-activating monoclonal antibodies (“mab”) against cancer antigens or cancer antigens with low tumor cell density.
Memorial Sloan-kettering Cancer Center |
01/22/15
20150023952 | Anti-addl monoclonal antibody and uses thereof
The present invention relates to antibodies that bind amyloid β-derived diffusible ligands, also known as addls. The antibodies of the invention are selective for addls, can penetrate the brain, and are useful in methods of detecting addls and diagnosing alzheimer's disease.
Merck Sharp & Dohme Corp. |
01/22/15
20150023951 | Anti-vegf antibodies
Humanized and variant anti-vegf antibodies and various uses therefor are disclosed. The anti-vegf antibodies have strong binding affinities for vegf; inhibit vegf-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo..
Genentech, Inc. |
01/22/15
20150023870 | Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to b-cell lymphomas and other diseases
Disclosed herein are compositions and methods of use comprising hexavalent dnl complexes. Preferably, the complexes comprise anti-cd20 and/or anti-cd22 antibodies or fragments thereof.
Ibc Pharmaceuticals, Inc. |
01/22/15
20150023568 | Computing systems, computer-readable media and methods of antibody profiling
Computing systems, computer-readable media and methods are disclosed. In the computing system, an image capture device captures an image of a protein array including spots of predetermined proteins, wherein some of the spots have bound to a biological material having individual-specific antibodies to form immune complexes and some of the immune complexes have interacted with a detection agent to generate a visible image therefrom.
Battelle Energy Alliance, Llc |
01/22/15
20150021208 | Measuring biological substance and measuring device therefor
Provided is a measuring method for a biological substance, a measuring chip, and a measuring device which exhibit improved electrical responsiveness and reliability. For example, the device or chip provided for measuring the amount of a biological substance in a liquid being measured comprises immobilized antibodies, a substance that is labeled with an ion-conductive compound and that is bonded to the antibodies, and an electrode containing a working electrode and a counter electrode, and the working electrode has a thin film on the surface thereof that contains a hydrocarbon group..
Panasonic Corporation |
01/15/15
20150018532 | Antibody
The invention relates to antibodies to aspergillus species and to methods of producing those antibodies. The invention also relates to the use of such antibodies in identifying the presence of the aspergillus species and to methods of treating an infection with the aspergillus species..
University Of Exeter |
01/15/15
20150018531 | Anti sez6 antibodies and methods of use
Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.. .
Stem Centrx, Inc. |
01/15/15
20150018529 | Sequence symmetric modified igg4 bispecific antibodies
The present disclosure relates to a symmetric bispecific antibody of the class igg4 comprising two heavy chains which each comprise a variable domain, ch1 domain and a hinge region, wherein in each heavy chain: the cysteine in the ch1 domain which forms an inter-chain disulphide bond with a cysteine in a light chain is substituted with another amino acid; and optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, wherein the constant region sequence of each heavy chain is similar or identical and the variable region in each heavy chain is different, formulations comprising the same, the use of each of the above in treatment and processes for preparing said antibodies and formulations.. .
Ucb Pharma S.a. |
01/15/15
20150018528 | Antibodies that bind peptidoglycan recognition protein 1
Disclosed herein is a method for identifying trem-1's ligand and antibodies, or fragments thereof, which are capable of modifying the function of trem-1's ligand. Antibodies that reduce or block trem-1 activation may be identified and selected using this method.
Novo Nordisk A/s |
01/15/15
20150018516 | Pro-drug form (p2pdox) of the highly potent 2-pyrrolinodoxorubicin conjugated to antibodies for targeted therapy of cancer
Disclosed are methods, compositions and uses of conjugates of prodrug forms of 2-pyrrolinodoxorubicin (p2pdox) with antibodies or antigen-binding fragments thereof (adcs), with targetable construct peptides or with other targeting molecules that are capable of delivering the p2pdox to a targeted cell, tissue or pathogen. Once delivered to the target cell, the adc or peptide conjugate is internalized, a highly toxic 2-pyrrolinodoxorubicin (2-pdox) is released intracellularly.
Immunomedics, Inc. |
01/15/15
20150018408 | Therapeutic antibodies and uses thereof
Provided herein are methods, compositions, and uses relating to inhibitors of stem cell factor. For example, provided herein are antibodies targeting stem cell factor and methods for treating fibrotic and tissue remodeling diseases..
The Regents Of The University Of Michigan |
01/15/15
20150018395 | Chimeric small molecules for the recruitment of antibodies to cancer cells
The present invention relates to chimeric chemical compounds which are used to recruit antibodies to cancer cells, in particular, prostate cancer cells or metastasized prostate cancer cells. The compounds according to the present invention comprise an antibody binding terminus (abt) moiety covalently bonded to a cell binding terminus (cbt) through a linker and optionally, a connector molecule..
Yale University |
01/15/15
20150018253 | Methods and compositions for selective labeling of different biotinylated targets within multicolor or multilabel assays
Disclosed are compositions and methods for the labeling of two or more targets with different labels. Specifically, disclosed are compositions for biotin and the protection of biotin within multilabel assays which employ the biotin-biotin binding protein binding relationship for each distinct label in relation to targets such as nucleic acids, polypeptides, antibodies or cells.
Affymetrix, Inc. |
01/15/15
20150018251 | Protein chips, preparation and use thereof
The present invention relates to the field of medicine, in particular of research and diagnosis. It relates more particularly to a novel tool for detecting antibodies in a biological sample originating from a mammal.
Universite Claude Bernard Lyon 1 |
01/15/15
20150018239 | Biomarker set for identifying a severe form of cancer
The present invention relates to a method for differentiating between i) a severe form of cancer and ii) a mild form of cancer, comprising a) determining the amounts of gene product of at least the genes coding for ribosomal protein s6 (rps6), nucleoside diphosphate kinase (nme/ndka), and caveolin-1, in a sample from a subject, b) comparing the amounts obtained in step a) to reference amounts, and c) differentiating between a severe form of cancer and a mild form of cancer, wherein an increased amount of products of the genes coding for rps6 and nme/ndka and a decreased amount of product of the gene coding for caveolin-1 are indicative of a severe form of cancer. The invention further relates to the use of antibodies specifically recognizing a polypeptide selected from the list consisting of rps6, nme/ndka, and caveolin-1, for differentiating between a severe form of cancer and a mild form of cancer.
Deutsches Krebsforschungszentrum |
01/15/15
20150018229 | Polymorphisms in the human gene for the multidrug resistance-associated protein 1 (mrp-1) and their use in diagnostic and therapeutic applications
The present invention relates to a polymorphic mrp-1 polynucleotide, genes or vectors comprising the polynucleotides and a host cell genetically engineered with the polynucleotide or gene. Also provided are methods for producing molecular variant polypeptides, cells capable of expressing a molecular variant polypeptide and a polypeptide encoded by the polynucleotide or the gene or obtainable by the method or cells produced herein.
Transgenomic, Inc. |
01/15/15
20150017738 | Means and methods of measuring parathyroid hormone in patients suffering from oxidative stress
Method for obtaining an antibody or antibody fragment to a conformational epitope specific for oxidized, inactive human parathyroid hormone and fragments thereof; a method for removal of oxidized, inactive human parathyroid hormone from a sample of body fluid; methods of determining the concentration of active parathyroid hormone in a sample, and an in vitro method of diagnosis of renal failure or secondary hyperthyroidism in patients on dialysis. The antibody is obtained by immunizing an animal with an immunogen containing parathyroid hormone or fragment thereof oxidized at methionines at positions 8, 18 or both; and a recovering of antibodies; whereby the complementary determining region of the antibody or antibody fragment or single chain antibody specifically recognizes a conformational epitope (antigenic determinant) which is a tertiary structure and only present on oxidized parathyroid hormone and fragments thereof only but not regular bioactive human parathyroid hormone, while the binding surface to the complementary binding region does not include any one of the oxidized methionines of human parathyroid hormone..
Immundiagnostik Ag |
01/15/15
20150017665 | Peptides and methods for detecting mpo-anca
The present invention relates to disorder-specific epitopes recognized by myeloperoxidase-anti-neutrophil cytoplasmic autoantibodies and the use of polypeptides comprising the epitopes in methods of diagnosing and monitoring autoimmune disorders associated with the autoantibodies.. .
The University Of North Carolina At Chapel Hill |
01/15/15
20150017633 | Methods and compositions to evaluate antibody treatment response
The present invention relates to methods and compositions to evaluate or assess the response of a subject to particular therapeutic treatment. More particularly, the invention provides methods to determine the response of subjects, or to adapt the treatment protocol of subjects treated with therapeutic antibodies. |
01/15/15
20150017230 | Anti-epithelial cell adhesion molecule (epcam) antibodies and methods of use thereof
An isolated monoclonal antibody or an antigen-binding fragment thereof is disclosed. The antibody or the antigen-binding fragment is characterized by: (a) having a specific binding affinity to epithelial cell adhesion molecule (epcam) comprising the amino acid sequence of seq id no: 1; (b) having a specific binding affinity to cancer cells expressing epcam said cancer cells being selected from the group consisting of oral cancer cells, nasopharyngeal cancer cells (npc), colorectal cancer cells, and ovarian cancer cells; and (c) having no binding affinity to human umbilical vein endothelial cell (huvec) and normal nasal mucosal epithelia (nnm).
Academia Sinica |
01/15/15
20150017188 | Cysteine engineered antibodies and conjugates
Where p is 1 to 4. Diagnostic and therapeutic uses for cysteine engineered antibody drug compounds and compositions are disclosed.. |
01/15/15
20150017187 | Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
Provided herein are antibodies comprising multiple non-natural amino acid residues at site-specific positions, compositions comprising the antibodies, methods of their production and methods of their use. The antibodies are useful for methods of treatment and prevention, methods of detection and methods of diagnosis..
Sutro Biopharma, Inc. |
01/15/15
20150017183 | Single domain antibodies as inhibitors of pcsk9
Antibodies (e.g., sdabs) binding to pcsk9 are described. Nucleic acids encoding such abs, host cells expressing such abs and pharmaceutical composition comprising same are described.
National Research Council Canada |
01/15/15
20150017178 | Anti-cd26 antibodies and uses thereof
The present invention pertains to novel antibodies capable of binding to cd26, as well as to their use as a medicament. Moreover, the present invention provides antibodies for use in treating and/or preventing graft-versus-host disease (gvhd), for use in treating aplastic anemia and/or for use in promoting engraftment after haematopoietic stem cell transplantation.
Adienne S.r.l. S.u |
01/15/15
20150017175 | Methods of administering anti-tnfalpha antibodies
Methods of treating disorders in which tnfα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (htnfα) are disclosed. The antibody may be administered with or without methotrexate.
Abbvie Biotechnology Ltd. |
01/15/15
20150017173 | Antibodies to human transmembrane proteins
The invention provides human transmembrane proteins (htmpn) and polynucleotides which identify and encode htmpn. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
Incyte Corporation |
01/15/15
20150017171 | Methods and agents for the diagnosis and treatment of hepatocellular carcinoma
The present invention relates to methods of diagnosing, and methods of treating, hepatocellular carcinoma in a subject. The invention also relates to polypeptide antagonists of plvap proteins, including humanized and chimeric antibodies that specifically bind plvap proteins, as well as compositions and kits comprising such polypeptide antagonists..
China Synthetic Rubber Corporation |
01/15/15
20150017169 | Sequence asymmetric modified igg4 bispecific antibodies
The present disclosure provides an asymmetric mixed antibody comprising two heavy chains or heavy chain fragments each comprising at least a variable region, a hinge region and a ch1 domain, wherein a first heavy chain or fragment thereof is a class igg4 and has: a the inter-chain cysteine at position 127, numbered according to the kabat numbering system, in the ch1 domain is substituted with another amino acid; and b optionally one or more of the amino acids positioned in the upper hinge region is substituted with cysteine, and wherein the second heavy chain or fragment thereof is characterised in that part or all of the chain has a different amino acid sequence to said first heavy chain in at least the region outside the variable region (for example the constant region), formulations comprising the same, therapeutic used of both of the above, and processes for preparing the antibodies and formulation.. .
Ucb Pharma S.a. |
01/15/15
20150017166 | Regulation of glucose metabolism using anti-cgrp antibodies
The present disclosure provides methods for the prevention or treatment of metabolic disorders. In exemplary embodiments, methods of administering an anti-cgrp antibody are provided, optionally in combination with a second agent, wherein peripheral and/or hepatic glucose utilization is increased, thereby preventing or treating diseases and disorders associated with insulin resistance.
Alderbio Holdings Llc |
01/15/15
20150017165 | Monoclonal antibodies that inhibit the wnt signaling pathway and methods of production and use thereof
Monoclonal antibodies against lrp6 and that block the wnt signaling pathway are disclosed. Methods of production and use thereof are also disclosed..
The Board Of Regents Of The University Of Oklahoma |
01/15/15
20150017162 | Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
In one aspect, the invention provides an isolated antibody, or antigen-binding fragment thereof, comprising a bioactive peptide amino acid sequence, wherein the bioactive peptide amino acid sequence is an inhibitor of the complement system and is fused to at least one of: (i) the amino terminal region of at least one of: a light chain variable region and/or a heavy chain variable region; or (ii) the carboxy terminal region of at least one of: a light chain constant region and/or a heavy chain constant region, wherein the antibody inhibits complement activation.. .
Omeros Corporation |
01/15/15
20150017155 | Aglycosyl anti-cd154 (cd40 ligand) antibodies and uses thereof
The invention relates to aglycosyl anti-cd154 antibodies or antibody derivatives, characterized by a modification at the conserved n-linked site in the ch2 domains of the fc portion of said antibody. The invention also relates to the treatment of immune response related diseases and inhibition of unwanted immune responses with such aglycosylated anti-cd154 antibodies or antibody derivatives thereof..
Biogen Idec Ma Inc. |
01/15/15
20150017154 | Anti-nerve growth factor antibodies and methods of preparing and using the same
A method of preparing an antibody suitable for use in a canine is provided. Also provided are caninised antibodies which specifically bind to canine neuronal growth factor (ngf) and neutralise the ability of canine ngf to bind to the p75 or trka canine ngf receptor.
Nvip Pty Ltd. |
01/15/15
20150017153 | Monoclonal antibodies that neutralize anthrax toxins
The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (lf), edema factor (ef), and/or protective antigen (pa). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies.
The United States Of America,as Represented By The Secretary, Dept. Of Health And Human Services |
01/08/15
20150011594 | Bin1 expression as a marker of cancer
Provided are methods for screening a subject for cancer. The methods involve obtaining a blood sample from the subject and determining a level of bridging integrator 1 (bind isoforms comprising exon 12a in the sample.
Sarcotein Diagnostics, Llc |
01/08/15
20150011567 | Phosphorylation of histones and uses thereof
Phosphorylation of histones was observed at certain tyrosine residues which have not been associated with epigenetic modification. These sites include h2b tyr37, h4 tyr88 and tyr 51 and h3 tyr99.
H. Lee Moffitt Cancer Center And Research Institute |
01/08/15
20150011479 | Alpha1 proteinase inhibitor peptides methods and use
The invention is directed to the use of peptides that can bind and block the interaction of α1 proteinase inhibitor (α1pi) and one or more molecules, for example antibodies to hiv-1 envelope proteins. The invention features methods of activating α1pi in a cell, methods of treating or preventing a disease or disorder in a subject, for example hiv-1 or aids. |
01/08/15
20150011431 | Humanized antibodies
The present disclosure provides humanized antibodies, including antibodies comprising an ultralong cdr3 (e.g. Bovine) and uses thereof..
The Scripps Research Institute |
01/08/15
20150010952 | Complementing cell lines
A packaging cell line that complements recombinant adenoviruses based on serotypes from subgroup b, preferably adenovirus type 35. The cell line may be derived from primary, diploid human cells that are transformed by adenovirus e1 sequences either operatively linked on one dna molecule or located on two separate dna molecules, the sequences being operatively linked to regulatory sequences enabling transcription and translation of encoded proteins.
Crucell Holland B.v. |
01/08/15
20150010946 | Polynucleotides encoding zcytor17 ligand antibodies
The present invention relates to zcytor17lig polynucleotide, polypeptide and anti-zcytor17 antibody molecules. The zcytor17lig is a novel cytokine.
Zymogenetics, Inc. |
01/08/15
20150010584 | Targeted delivery of autoantigens to b cell populations
The present invention is related to compositions and methods to stimulate the immune system. For example, antigen-specific antibodies may be produced by stimulating b cell populations with specific antigenic compounds, such as an adjuvant comprising a macromolecule capable of activating a toll-like receptor (tlr).
The University Of Massachusetts |
01/08/15
20150010581 | Combined therapy of alpha-1-antitrypsin and temporal t-cell depletion for preventing graft rejection
The present invention provides compositions and methods for the prevention and treatment of aggressive immune processes to life-saving grafts, such as xenograft rejection, and for attenuating host responses in transplantation of tissues, cells and organs. More specifically, the compositions and methods of the present invention relate to combined therapies comprising treatment of alpha-1-antitrypsin (aat) and temporary t-cell depletion including but not limited to anti-cd4 and anti-cd8 antibodies..
Ben Gurion University Of The Negev Research And Development Authority |
01/08/15
20150010580 | Antibodies to clostridium difficile toxins
The present invention provides an antibody composition comprising ovine antibodies, for use in the prevention or treatment of c. Difficile infection wherein the antibodies bind to a c.
Health Protection Agency |
01/08/15
20150010579 | Treatment and prevention of gardnerella vaginalis infections
The present invention is drawn to the nucleic and amino acid sequences encoding vaginolysin (vly) toxin from gardnerella vaginalis, and biologically active fragments and variants thereof. The invention is also directed to anti-vly antibodies and to their use therapeutically and in a new elisa assay of vly toxin.
The Trustees Of The University Of Columbia In The City Of New York |
01/08/15
20150010574 | Anti-igf antibodies
Antibody molecules, in particular fully human antibodies that bind to human igf-1 and cross-react with igf-2 such that binding of igf-1 and igf-2 to the igf-1 receptor is prevented and igf-1 receptor-mediated signaling is inhibited. The antibodies do not bind to insulin and thus do not affect the mitogenic properties of insulin that are mediated by its binding to the insulin receptors.
Boehringer Ingelheim International Gmbh |
01/08/15
20150010573 | Il-17 antibody formulation
The present invention provides stabilized pharmaceutical formulations for anti-il-17 antibodies, comprising e.g. Citrate, sodium chloride and polysorbate-80 at ph 5.7.
Eli Lilly And Company |
01/08/15
20150010572 | Ang-2 specific antibodies and uses thereof
Provided are an anti-ang-2 antibody or antigen-binding fragment thereof that specifically binds to an angiogenesis-inducing factor angiopoietin-2 (ang-2), related compositions and pharmaceutical compositions, and methods for using such compositions and pharmaceutical compositions.. .
Samsung Electronics Co., Ltd. |
01/08/15
20150010571 | Rspo binding agents and uses thereof
The present invention relates to rspo-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human rspo proteins and modulate β-catenin activity.
Oncomed Pharmaceuticals, Inc. |
01/08/15
20150010568 | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing gdf8 and or activin a
The present invention provides compositions and methods which involve specifically antagonizing gdf8 and activin a. In certain embodiments, compositions are provided which comprise a gdf8-specific binding protein and an activin a-specific binding protein.
Regeneron Pharmaceuticals, Inc. |
01/08/15
20150010566 | Influenza a virus specific antibodies
The invention relates to isolated, synthetic or recombinant antibodies and functional parts thereof specific for multiple influenza a virus subtypes. The invention further relates to the use of such antibodies for diagnosis of an influenza a virus infection and as a medicament and/or prophylactic agent for at least in part treating or alleviating symptoms of an influenza a virus infection.. |
01/08/15
20150010565 | Rspo binding agents and uses thereof
The present invention relates to rspo-binding agents and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human rspo proteins and modulate β-catenin activity.
Oncomed Pharmaceuticals, Inc. |
01/08/15
20150010564 | Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
Disclosed herein are methods of using anti-ilt5 antibodies and ilt5-binding fragments thereof for the treatment of various diseases and for use as immunostimulatory adjuvants.. .
Merck Sharp & Dohme Corp. |
01/08/15
20150010560 | Human pac1 antibodies
Antibodies and antigen-binding fragments thereof that bind to human pac1 are provided. Nucleic acids encoding the antibodies and antigen-binding fragments thereof, vectors, and cells encoding the same are also provided.
Amgen Inc. |
01/08/15
20150010559 | Anti-tlr4 antibodies and methods of use thereof
This invention relates generally to antibodies that specifically bind toll-like receptor 4 (tlr-4), and to methods of using the anti-tlr4 antibodies as therapeutics and to methods of using the anti-tlr4 antibodies in methods of preventing transplant rejection and/or prolonging survival of transplanted biological material.. .
Novimmune S.a. |
01/08/15
20150010553 | Methods of treating inflammatory diseases using antibodies that bind both il-17a and il-17f
The present invention relates to blocking, inhibiting, reduceing, antagonizing or neutralizing the activity of il-17a and il-17f. Il-17a and il-17f are cytokines that are involved in inflammatory processes and human disease.
Zymogenetics, Inc. |
01/08/15
20150010547 | Treatment of allergic diseases with recombinant antibodies
Recombinant antibodies (including binding fragments thereof) that bind ige are described, along with compositions and methods of using the same in the treatment of subjects in need thereof, including subjects afflicted with atopic dermatitis, allergic rhinitis, allergic conjunctivitis, urticaria, gastro-intestinal inflammation, or oral-pharyngeal inflammation. In some embodiments, the antibody is a single chain variable fragment (scfv) or a disulfide linked variable fragment (sdfv).
North Carolina State University |
01/08/15
20150010542 | Antibodies to toso
The present invention provides methods and compositions for modulating toso activity and treating diseases and disorders in which toso is implicated. Such methods and compositions include the use of one or more antibodies that bind to a toso protein or to a ligand of a toso protein..
University Health Network |
01/08/15
20150010539 | Anti-cd25 antibodies and their uses
The present disclosure relates to antibodies directed to cd25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis.. .
Abbvie Biotherapeutics Inc. |
01/08/15
20150010538 | Anti-cd25 antibodies and their uses
The present disclosure relates to antibodies directed to cd25 and uses of such antibodies, for example to suppress organ transplant rejection or to treat multiple sclerosis.. .
Abbvie Biotherapeutics Inc. |
01/08/15
20150010536 | Humanized pai-1 antibodies and uses thereof
The present application relates to compositions of humanized anti-pai-1 antibodies and antigen-binding fragments thereof which convert pai-1 to its latent form. One aspect relates to antibodies having one or more modifications in at least one amino acid residue of at least one of the framework regions of the variable heavy chain, the variable light chain or both.
Cisthera, Incorporated |
01/08/15
20150010516 | Novel msc surface marker
The present invention relates to the use of at least one antibody which binds to the susd2 antigen, or to functional fragments of the antibody, in combination with at least one of the following: an antibody which binds to cd140b, an antibody which binds to cd56, and/or an antibody which binds to tnap, or functional fragments thereof, for isolation of mesenchymal stem cells, especially those having particularly chondrocytic and osteogenic differentiation potential. The invention further relates to processes for isolating such stem cells using these antibodies.
Eberhard-karls-universitaet Tuebingen Universitaetsklinikum |